Date: 06th August, 2026

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

<u>Sub.:</u> Press Release issued by Fredun Pharmaceuticals Limited

Dear Sir/ Madam,

Please find enclosed press release titled "***Fredun Pharmaceuticals Delivers Stellar Q1 FY27 Performance; Revenue Jumps 90%, EBITDA Surges 93% and Profit Rises 95% YoY***" issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records.

Thanking you,

Yours truly,

For **Fredun Pharmaceuticals Limited**

FREDUN NARIMAN MEDHORA
Digitally signed by FREDUN NARIMAN MEDHORA
Date: 2026.08.06 13:26:06 +05'30'

Fredun Nariman Medhora
Managing Director
DIN: 01745348

Fredun Pharmaceuticals Delivers Stellar Q1 FY27 Performance; Revenue Jumps 90%, EBITDA Surges 93% and Profit Rises 95% YoY

Mumbai – 06 August, 2026: – Fredun Pharmaceuticals Limited (BSE: FREDUN | 539730), one of India's leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products.

Key Financial Highlights

	Standalone		
Particulars (₹ Cr)	**Q1 FY27**	**Q1 FY26**	**YoY Growth**
Total Income	228.25	119.86	⬆ 90.44%
EBITDA	32.78	16.99	⬆ 92.90%
EBITDA Margin (%)	14.36%	14.18%	⬆ 18 Bps
Net Profit	13.17	6.77	⬆ 94.63%
Net Profit margin (%)	5.77%	5.64%	⬆ 12 Bps
EPS Basic (₹)	23.89	14.33	⬆ 66.71%

Commenting on the strong financial performance Mr. Fredun Medhora, Managing Director, said,

"Q1 FY27 has set a strong tone for the year, with robust growth in both revenue and profitability. More importantly, the quarter reinforces our belief that the long-term investments we have made across the business are beginning to translate into tangible outcomes. It also validates the direction in which we have been building the Company over the last few years.

We have always believed in building the business with a long-term perspective. Our objective has never been to chase short-term growth, but to create a diversified healthcare company with multiple engines of growth. As we continue to expand our branded portfolio, enter newer healthcare categories and strengthen our manufacturing capabilities, we believe we are laying the foundation for the next phase of growth.

The opportunities ahead remain significant. Healthcare continues to evolve rapidly, creating demand for differentiated products, specialised therapies and preventive healthcare solutions. With the capabilities we have built and the strategic investments already in place, we remain optimistic about the future and committed to delivering sustainable growth while creating long-term value for our shareholders."

Recent Key Business Highlights

Allotment of Bonus Equity Shares

- On **17th July 2026,** the Company allotted **1.10 crore** Bonus Equity Shares in a **2:1 ratio** to eligible shareholders.
- Issued and paid-up equity share capital increased from **55.13 lakh shares to 1.65 crore** shares following the bonus allotment.

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY26, Fredun reported total revenues of ₹639.12 Cr, with an EBITDA of ₹94.79 Cr and a PAT of ₹33.21 Cr.

Disclaimer

For Further Information Please Contact

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com